Long-term outcomes of initial antidepressant drug choice in a "Real World" randomized trial

Archives of Family Medicine

Volumn 8, Issue 4, 1999, Pages 319-325

  Simon, Gregory E ^a,b   Heiligenstein, John ^c   Revicki, Dennis ^d   Vonkorff, Michael ^a   Katon, Wayne J ^b   Ludman, Evette ^a   Grothaus, Louis ^a   Wagner, Edward ^a  

^a CENTER FOR HEALTH STUDIES   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; ECONOMICS; FEMALE; HUMAN; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; UNITED STATES;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DESIPRAMINE; FEMALE; FLUOXETINE; HUMANS; IMIPRAMINE; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0033238134     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.8.4.319     Document Type: Article

References (26)

1. Glaser M. Annual Rx survey. Drug Top. 1997;141:45-53.
2. Ormel J, VonKorff M, Ustun TB, Pini S, Korten A, Oldehinkel T. Common mental disorders and disability across cultures. JAMA. 1994;272:1741-1748.
3. Spitzer R, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders. JAMA. 1995;274:1511-1517.
4. Simon G, Ormel J, VonKorff M, Barlow W. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry. 1995;152:352-357.
5. Unutzer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients age 65 and over: a four-year prospective study. JAMA. 1997;277:1618-1623.
6. Keller MB, Lavori PW, Klerman GL, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry. 1986;43:458-466.
7. Simon G, VonKorff M, Wagner EH, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry. 1993;15:399-408.
8. Katon W, VonKorff M, Lin E, Bush T, Ormel J. Adequacy and duration of antide-pressant treatment in primary care. Med Care. 1992;30:67-76.
9. Song F, Freemantle N, Sheldon T, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ. 1993;306:683-687.
10. Workman E, Short D. Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. J Clin Psychiatry. 1993;54:5-12.
11. Greenberg R, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD. A metaanalysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis. 1994;182:547-551.
12. Montgomery S, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol. 1994;9:47-53.
13. Pande A, Sayler ME. Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol. 1993;8:267-269.
14. LePen C, Levy E, Ravily V, Beuzen JN, Meurgey F. The cost of treatment dropout in depression. J Affect Disord. 1994;31:1-18.
15. Jonsson B, Bebbington PE. What price depression: the cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry. 1994;164:665-673.
16. Bentkover JDFJ. Cost analysis of paroxetine vs imipramine in major depression. PharmacoEconomics. 1996;8:223-232.
17. Woods S, Rizzo JA. Cost-effectiveness of antidepressant treatment reassessed. Br J Psychiatry. 1997;170:257-263.
18. Revicki D, Brown RE, Keller MB, Gonzales J, Culpepper L, Hales RE. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry. 1997;58:47-58.
19. Simon G, VonKorff M, Heiligenstein JH, et al. Initial antidepressant selection in primary care: effectiveness and cost of fluoxetine vs. tricyclic antidepressants. JAMA. 1996;275:1897-1902.
20. Simon G, Wagner E, VonKorff M. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. J Clin Epidemiol. 1995;48:363-373.
21. Spitzer RL, Williams JBW, Gibbon M, First MB. User's Guide for the Structured Clinical Interview for DSM-III-R. Washington, DC: American Psychiatric Press; 1990.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
23. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
24. Williams JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45:742-747.
25. Derogatis L, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist: a measure of primary symptom dimensions. In: Pichot P, ed. Psychological Measurements in Psychopharmacology: Problems in Psychopharmacology. Basel, Switzerland: Kargerman; 1974:79-110.
26. Ware J, Snow KK, Kosinski M, Gandek B. The MOS SF-36 Health Survey: Manual and Interpretation Guide. Boston, Mass: The Health Institute, New England Medical Center; 1993.